India’s largest generics maker Ranbaxy Laboratories announced on 27 June 2014 that its subsidiary, US-based Ohm Laboratories (Ohm), had received approval from the US Food and Drug Administration (FDA) for generic valsartan.
Generic valsartan approved in US
Generics/News
|
Posted 01/08/2014
0
Post your comment
The drug is a generic of Novartis’s heart treatment drug, Diovan (valsartan), which is indicated for the treatment of high blood pressure and heart failure.
Ohm has received first-to-file FDA approval, giving the company 180 days of marketing exclusivity to manufacture and market generic valsartan in dosages of 40, 80, 160 and 320 mg tablets.
The originator brand, Diovan, has annual sales of US$2.19 billion, according to IMS Health.
The launch of the generic drug has been on hold since September 2012, when Diovan’s patent expired due to regulatory problems with the FDA [1]. However, with the Ohm site successfully passing an FDA inspection in October 2013, Ranbaxy may now be able to get back on track with some of its product launches, despite ongoing problems at its India-based facilities at Paonta Sahib, Dewas and Mohali [2].
Ranbaxy’s next big launch is expected to be a generic version of AstraZeneca’s blockbuster stomach-acid-relief drug, Nexium (esomeprazole), which had global sales in 2013 of US$3.9 billion, and was expected in May 2014.
Related article
Mylan debuts first generic Diovan HCT and Antivert in USA
References
1. GaBI Online - Generics and Biosimilars Initiative. Mylan sues FDA over Ranbaxy’s generic Diovan exclusivity [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Aug 1]. Available from: www.gabionline.net/Generics/News/Mylan-sues-FDA-over-Ranbaxy-s-generic-Diovan-exclusivity
2. GaBI Online - Generics and Biosimilars Initiative. Good news for Ranbaxy plant in US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Aug 1]. Available from: www.gabionline.net/Generics/News/Good-news-for-Ranbaxy-plant-in-US
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.
Source: Ranbaxy
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment